Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.
Quiz|Articles|October 23, 2026
OncLive Weekly News Quiz (10/23/2026): Did You Miss Crucial Rectal, Bladder, and Kidney Cancer Updates?
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
The FDA granted accelerated approval to dostarlimab-gxly (Jemperli) for adult patients with stage II or III mismatch repair–deficient (dMMR) or microsatellite instability–high (MSI-H) locally advanced rectal cancer, based on data from the phase 2 AZUR-1 trial (NCT05723562). What was the primary end point of AZUR-1?
Advertisement
Related to this article
Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.
Patients with resected RCC given adjuvant durvalumab with or without tremelimumab described persistent low-grade toxicities as most disruptive to QOL.
Gastrointestinal oncologists weigh HER2 testing practices, the order of HER2-directed therapies, and emerging agents for metastatic colorectal cancer.
The FDA has granted traditional approval to pembrolizumab for unresectable/metastatic TMB-H solid tumors.
The FDA granted fast track designation to SBE303 for locally advanced or metastatic urothelial cancer previously treated with enfortumab vedotin.
The European Commission approved pembrolizumab plus enfortumab vedotin for muscle-invasive bladder cancer, irrespective of cisplatin eligibility.
Andrea Cercek, MD, discusses the FDA approval of dostarlimab and its significance for dMMR locally advanced rectal cancer management.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Full Approval to Pembrolizumab for Unresectable/Metastatic TMB-H Solid Tumors
2
HER2+ mCRC Treatment Sequencing Favors Tucatinib Plus Trastuzumab Before T-DXd
3
SBE303 Receives FDA Fast Track Designation in Pretreated Urothelial Cancer
4
FDA Grants Orphan Drug Designation to Onvansertib for Chronic Myelomonocytic Leukemia
5